Page last updated: 2024-11-05

thalidomide and Thrombophilia

thalidomide has been researched along with Thrombophilia in 15 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Thrombophilia: A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.

Research Excerpts

ExcerptRelevanceReference
"Venous thromboembolism (VTE) is a major complication of myeloma therapy recently observed with the increasing use of up-front thalidomide and dexamethasone (thal-dex)."9.14Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. ( Catalano, L; Cavo, M; Cini, M; Gozzetti, A; Legnani, C; Masini, L; Palareti, G; Patriarca, F; Tacchetti, P; Tosi, P; Valdré, L; Zamagni, E, 2010)
"Lenalidomide, a derivate of thalidomide, has recently been approved in Europe for the treatment of patients with multiple myeloma."8.84Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates. ( Gieseler, F, 2008)
"The therapeutic use of thalidomide in patients with multiple myeloma is often complicated by the development of venous thromboembolism."7.75Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. ( Claxton, D; Fink, LM; Ibrahim, S; Talamo, GP; Tricot, GJ; Zangari, M, 2009)
"Venous thromboembolism (VTE) is a major complication of myeloma therapy recently observed with the increasing use of up-front thalidomide and dexamethasone (thal-dex)."5.14Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. ( Catalano, L; Cavo, M; Cini, M; Gozzetti, A; Legnani, C; Masini, L; Palareti, G; Patriarca, F; Tacchetti, P; Tosi, P; Valdré, L; Zamagni, E, 2010)
" We report the results of a prospective randomized trial of 62 newly diagnosed MM patients tested at baseline for hypercoagulability and treated with intensive chemotherapy with or without thalidomide in a randomized fashion."5.10Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. ( Anaissie, E; Badros, A; Barlogie, B; Desikan, R; Fassas, A; Fink, L; Mehta, P; Morris, C; Saghafifar, F; Siegel, E; Toor, A; Tricot, G; Whitfield, D; Zangari, M, 2002)
"Lenalidomide, a derivate of thalidomide, has recently been approved in Europe for the treatment of patients with multiple myeloma."4.84Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates. ( Gieseler, F, 2008)
" Established risk factors in IBD colitis inpatients with TE included: indwelling catheter (4/10), first-degree family member with TE (2/10), hereditary thrombophilia (3/10), smoking (1/10), oral contraceptive (1/5 females), and thalidomide (1/10)."3.79Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease. ( Atkinson, BJ; Bousvaros, A; Harney, KM; Levine, AE; Lightdale, JR; Trenor, CC; Verhave, M; Zitomersky, NL, 2013)
"The therapeutic use of thalidomide in patients with multiple myeloma is often complicated by the development of venous thromboembolism."3.75Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. ( Claxton, D; Fink, LM; Ibrahim, S; Talamo, GP; Tricot, GJ; Zangari, M, 2009)
"Thrombosis was not associated with inferior progression-free survival (PFS) or overall survival (OS), apart from inferior OS for patients with arterial events (aHR, 1."2.94Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. ( Bradbury, CA; Cairns, DA; Child, JA; Cook, G; Craig, Z; Davies, FE; Drayson, MT; Gregory, WM; Hockaday, A; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Morgan, GJ; Owen, RG; Paterson, A; Pawlyn, C, 2020)
"Thalidomide is a synthetic glutamic acid derivative first introduced in 1956 in Germany as an over the counter medications."2.50[Current therapeutic indications of thalidomide and lenalidomide]. ( Cosiglio, FJ; Ordi-Ros, J, 2014)

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (53.33)29.6817
2010's5 (33.33)24.3611
2020's2 (13.33)2.80

Authors

AuthorsStudies
Cornell, RF1
Goldhaber, SZ1
Engelhardt, BG1
Moslehi, J1
Jagasia, M1
Harrell, S1
Rubinstein, SM1
Hall, R1
Wyatt, H1
Piazza, G1
Bradbury, CA1
Craig, Z1
Cook, G1
Pawlyn, C1
Cairns, DA1
Hockaday, A1
Paterson, A1
Jenner, MW1
Jones, JR1
Drayson, MT1
Owen, RG1
Kaiser, MF1
Gregory, WM1
Davies, FE1
Child, JA1
Morgan, GJ1
Jackson, GH1
Storrar, NPF1
Mathur, A1
Johnson, PRE1
Roddie, PH1
Zitomersky, NL1
Levine, AE1
Atkinson, BJ1
Harney, KM1
Verhave, M1
Bousvaros, A1
Lightdale, JR1
Trenor, CC1
Ordi-Ros, J1
Cosiglio, FJ1
Kovacs, MJ1
Davies, GA1
Chapman, JA1
Bahlis, N1
Voralia, M1
Roy, J1
Kouroukis, CT1
Chen, C1
Belch, A1
Reece, D1
Zhu, L1
Meyer, RM1
Shepherd, L1
Stewart, KA1
Gieseler, F1
Talamo, GP1
Ibrahim, S1
Claxton, D1
Tricot, GJ1
Fink, LM1
Zangari, M3
Cini, M1
Zamagni, E1
Valdré, L1
Palareti, G1
Patriarca, F1
Tacchetti, P1
Legnani, C1
Catalano, L1
Masini, L1
Tosi, P1
Gozzetti, A1
Cavo, M1
Rodeghiero, F1
Elice, F2
Kaushal, V1
Kaushal, GP1
Melkaveri, SN1
Mehta, P2
Potenza, L1
Luppi, M1
Morselli, M1
Saviola, A1
Ferrari, A1
Riva, G1
Longo, G1
Marietta, M1
Torelli, G1
Fink, L2
Tricot, G2
Pitini, V1
Arrigo, C1
Aloi, G1
Azzarello, D1
La Gattuta, G1
Saghafifar, F1
Anaissie, E1
Badros, A1
Desikan, R1
Fassas, A1
Morris, C1
Toor, A1
Whitfield, D1
Siegel, E1
Barlogie, B1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Phase III Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients With Multiple Myeloma[NCT00049673]Phase 3332 participants (Actual)Interventional2002-10-15Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

3 reviews available for thalidomide and Thrombophilia

ArticleYear
[Current therapeutic indications of thalidomide and lenalidomide].
    Medicina clinica, 2014, Apr-22, Volume: 142, Issue:8

    Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents; Antineoplastic Agents; Collagen Diseases; End

2014
Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates.
    Thrombosis and haemostasis, 2008, Volume: 99, Issue:6

    Topics: Antineoplastic Agents; Blood Coagulation; Fibrinolytic Agents; Humans; Lenalidomide; Multiple Myelom

2008
Thrombosis in multiple myeloma.
    Expert review of anticancer therapy, 2007, Volume: 7, Issue:3

    Topics: Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Agents; Blood Coagulation Factors; Cytokines

2007

Trials

5 trials available for thalidomide and Thrombophilia

ArticleYear
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
    British journal of haematology, 2020, Volume: 190, Issue:4

    Topics: Aged; Comorbidity; Consolidation Chemotherapy; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Imm

2020
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
    Blood, 2020, 08-27, Volume: 136, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; De

2020
Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10.
    British journal of haematology, 2015, Volume: 168, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Combined Modality The

2015
Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
    European journal of haematology, 2010, Volume: 84, Issue:6

    Topics: Activated Protein C Resistance; Adult; Aged; Anticoagulants; Case-Control Studies; Dexamethasone; Fa

2010
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2002, Volume: 13, Issue:3

    Topics: Activated Protein C Resistance; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood C

2002

Other Studies

7 other studies available for thalidomide and Thrombophilia

ArticleYear
Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens.
    British journal of haematology, 2019, Volume: 185, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dise

2019
Risk factors, morbidity, and treatment of thrombosis in children and young adults with active inflammatory bowel disease.
    Journal of pediatric gastroenterology and nutrition, 2013, Volume: 57, Issue:3

    Topics: Adolescent; Adult; Antibodies, Anticardiolipin; Anticoagulants; Catheterization; Catheters, Indwelli

2013
Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2009, Volume: 20, Issue:5

    Topics: Activated Protein C Resistance; Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Combined Che

2009
Thalidomide and thrombosis.
    Pathophysiology of haemostasis and thrombosis, 2003, Volume: 33 Suppl 1

    Topics: Humans; Incidence; Neoplasms; Thalidomide; Thrombophilia; Thrombosis

2003
Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology.
    Journal of thrombosis and haemostasis : JTH, 2004, Volume: 2, Issue:2

    Topics: Angiogenesis Inhibitors; Apoptosis; Caspase 3; Caspases; Cell Size; Cell Survival; Cells, Cultured;

2004
Thrombotic complications associated with thalidomide in multiple myeloma: an old problem with new questions and quandaries in decision-making.
    Thrombosis and haemostasis, 2004, Volume: 91, Issue:4

    Topics: Aged; Decision Making; Female; Humans; Male; Middle Aged; Multiple Myeloma; Practice Guidelines as T

2004
Diabetic foot disease in a patient with multiple myeloma receiving thalidomide.
    Haematologica, 2002, Volume: 87, Issue:2

    Topics: Angiogenesis Inhibitors; Collateral Circulation; Combined Modality Therapy; Diabetes Mellitus, Type

2002